Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet

GlobeNewswireMay 1 04:05

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 From the ALG-097558 Phase 1 Study

Globe NewswireApr 26 04:05

Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet

GlobeNewswireApr 25 20:00

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutic

GlobeNewswireApr 9 20:00

Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects

Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects

BenzingaApr 3 20:18

Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada's CADTH

Seeking AlphaApr 2 20:59